I must post this information. On June 5, 2013, the organization Focus on Mantle Cell Lymphoma (http://www.focusonmcl.org/) along with Lymphoma Research Foundation (http://www.lymphoma.org/site/pp.asp?c=bkLTKaOQLmK8E&b=6296735) released the most current information available today for MCL. I am so excited to read research is advancing at such a fast pace in outwitting our cancer. When I try to comprehend what these new treatments do, all I can imagine is a cat and mouse game. I am amazed at the intellect and genius of our research teams!
Our hope is growing!! I read more and more stories about survivors’ continuing success in complete remission from MCL. Every once in a while, I also hear the national renowned MCL doctors use the “C” word, cure. Many doctors believe they are coming closer and closer in curing mantle cell lymphoma. What great news!
New Treatment For Mantle Cell Lymphoma
“On June 5, 2013, the U.S. Food and Drug Administration (FDA) approved lenalidomide (Revlimid) for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies. Lenalidomide currently represents the first and only oral therapy for mantle cell lymphoma, which is a rare, B-cell non-Hodgkin lymphoma. Mantle cell lymphoma comprises about five percent of all non-Hodgkin lymphomas and is usually diagnosed as a late-stage disease that has typically spread to the gastrointestinal tract and bone marrow.
The Lymphoma Research Foundation (LRF) has developed a series of educational resources for mantle cell lymphoma, ranging from disease-specific fact sheets and videos to archived webcasts.
- Mantle Cell Lymphoma Fact Sheet
- Relapsed/Refractory Mantle Cell Lymphoma Fact Sheet
- Non-Hodgkin Lymphoma Booklet
- Mantle Cell Lymphoma (Michael E. Williams, MD, University of Virginia Cancer Center)
- Mantle Cell Lymphoma (Leo I. Gordon, MD, Northwestern University)
To learn more about mantle cell lymphoma, visit LRF’s disease-specific website or call the LRF Helpline at (800) 500-9976 to speak with a trained staff member. For complete details on the FDA approval, visit: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm355438.htm?source=govdelivery.“